Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

'Back to School' Pharma Forum 2015

Life Sciences Group
Where Mississauga Convention Centre
75 Derry Road West
Mississauga, ON
Get directions


As a leader with a wealth of knowledge in this sector, Fasken Martineau invites you to its 2nd annual "Back to School" Pharma Forum on Thursday, September 24, 2015 in Mississauga, Ontario.

The topics discussed during this half-day forum will be presented by Canada's leading lawyers in the Life Sciences sector. The "Back to School" Pharma Forum, moderated by Christelle Gedeon, will feature relevant and interactive sessions on the following:

The Interface between Intellectual Property and Competition Law

Presented by Ingrid VanderElst and Huy Do

There is an inherent tension between intellectual property, which consists of exclusionary rights, and competition law and policy, which seeks to include competitors in the marketplace. During this presentation, we will discuss the specific challenges faced by the life sciences industry in this regard, including such topics as product hopping, pooling and cross-licensing arrangements and pay-for-delay settlements. The discussion will include a consideration of the proposed changes to the Competition Bureau's IP Enforcement Guidelines and insights on the current focus of the Competition Bureau.

What's new in Product Liability for the Life Sciences Industry?

Presented by Peter Pliszka

Product liability lawsuits are a fact of life for life sciences companies. Whether commercial disputes between companies in the supply chain or class action claims for personal injury damages, product liability claims can threaten a company’s reputation and bottom-line.  During this presentation, we will discuss current trends in product liability lawsuits, including the types of actions we are seeing, the approaches of the courts and damages awards.

The Role of the Minister in resolving disputes with Health Canada

Presented by Dan Brock 

Understanding the role, responsibility and priorities of the Minister of Health (and her/his political staff) can be key to resolving ‘business-critical’ issues with the Department.  Knowing when/if to raise your issue to the political level, and how best to present it, can make the difference in effective issue management for Health Canada stakeholders.  Dan Brock, the Chair of Fasken’s federal Government Relations and Strategy practice will discuss some key considerations for developing effective strategies for managing and resolving disputes with Health Canada.

Personalized medicine - Speed Bumps on the Road Ahead?

Presented by Richard Y. Cheung

Personalized medicine, the customization of medical therapy based on specific characteristics of each patient, is a substantial and growing market that has been described as the future of medicine. Given the substantial resources that drug and device companies have invested in developing targeted or precision therapies, this presentation will consider some of the key topics affecting the industry, including: (i) how recent decisions of the Federal Court and Practice Notices issued by the Canadian Intellectual Property Office may impact strategies to protect personalized medicine innovations; and (ii) the regulatory and market access challenges facing companies operating in the personalized medicine industry in Canada.

Developments in Regulatory Compliance - What's Changed since Bill C-17?

Presented by Timothy Squire

It has been almost a year since the implementation of Bill C-17 and the substantial new investigative and enforcement powers granted to Health Canada.  Has anything really changed?  This presentation will examine the impact of Bill C-17 to date and what other stakeholders in the industry have done in response to this new legislation.  The discussion will also cover other recent and anticipated regulatory developments, including plain language labelling, mandatory drug shortage reporting, the status of the long awaited orphan drug regime, and other new and anticipated Health Canada transparency initiatives.

Who should attend?

  • Presidents, CEOs, CFOs and General Counsel of pharmaceutical companies
  • VPs/Directors of Market Access and Government Affairs
  • VPs/Directors of Ethics/Compliance
  • VPs/Directors of Regulatory
  • VPs/Directors of Marketing/Communication/Public Affairs
  • VPs/Directors of Sales


  • 8:00 am - 9:00 am    Registration and Breakfast
  • 9:00 am - 12:00 pm  Programme
  • 12:00 pm - 1:00 pm  Networking Lunch